Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy

NCT07205536

Status	RECRUITING
Phase	Phase 2
Sponsor	Affiliated Hospital of Nantong University
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (6)

- Aged 18-75 years at the time of giving informed consent both sexes eligible
- Histologically or cytologically confirmed thoracic tumor (esophageal or lung cancer)
- Investigator judges the patient suitable for treatment with mecapegfilgrastim injection or leucogen tablets
- Expected survival \> 3 months
- Signed informed consent; willing and able to comply with protocol-mandated visits

... and 1 more (see full listing online)

Exclusion (4)

- Pregnant or lactating women
- Known hypersensitivity to mecapegfilgrastim, pegylated or non-pegylated rhG-CSF, or any E. coli-derived product
- Any severe comorbidity that, in the investigator's opinion, compromises patient safety or ability to complete the study
- Any other condition that, in the investigator's judgment, could interfere with study conduct or interpretation of results

Locations (1 total)

Affiliated Hospital of Nantong University, Nantong, Jiangsu, China